NO CONCLUSIVE EVIDENCE FROM RANDOMISED CONTROLLED TRIALS TO INFORM SECOND-LINE TREATMENT OPTIONS SURVIVAL AND CLINICAL BENEFITS, IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL

被引：0
|
作者：
Mason, M. [1 ]
Freemantle, N. [2 ]
Parnaby, A. [3 ]
Hogberg, D. [4 ]
机构：
[1] Cardiff Univ, Sect Oncol & Palliat Med, Cardiff, S Glam, Wales
[2] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England
[3] Sanofi Aventis, Hlth Econ & Reimbursement, Paris, France
[4] I3 Innovus, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 37 条
  • [1] NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL
    Mason, M.
    Freemantle, N.
    Parnaby, A.
    Hogberg, D.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
  • [2] A PHARMACOECONOMIC APRAISAL OF CABAZITAXEL VERSUS ABIRATERONE FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PROGRESSING AFTER THE TREATMENT WITH DOCETAXEL: A SYSTEMATIC REVIEW
    Bektur, C.
    Nurgozhin, T.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A70 - A70
  • [3] EVIDENCE PROVIDED BY NON-RANDOMISED TRIALS IS NOT CONCLUSIVE ON THE EFFICACY OF 2ND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC)
    Freemantle, N.
    Mason, M.
    Jasso-Mosqueda, J.
    Nixon, F.
    Budhia, S.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 301 - 301
  • [4] Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Giampaolo, Maria Anna
    Segati, Romana
    Valduga, Francesco
    Cetto, Gianluigi
    Galligioni, Enzo
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (02) : 152 - 156
  • [5] Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer
    Lainakis, George
    Nikos, Antoniou
    Gerassimos, Allvizatos
    Michael, Chrisofos
    Iraklis, Mitsoyiannis
    Konstantinos, Livadas
    Ioannis, Varkarakis
    Harilaos, Katsifotis
    Dimopoulos, Meletios A.
    Bamias, Aristotelis
    [J]. UROLOGY, 2008, 71 (06) : 1181 - 1185
  • [6] Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
    Nelius, Thomas
    Klatte, Tobias
    de Riese, Werner
    Haynes, Allan
    Filleur, Stephanie
    [J]. MEDICAL ONCOLOGY, 2010, 27 (02) : 363 - 367
  • [7] Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
    Thomas Nelius
    Tobias Klatte
    Werner de Riese
    Allan Haynes
    Stephanie Filleur
    [J]. Medical Oncology, 2010, 27 : 363 - 367
  • [8] Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
    Ben Kearns
    Myfanwy Lloyd Jones
    Matt Stevenson
    Chris Littlewood
    [J]. PharmacoEconomics, 2013, 31 : 479 - 488
  • [9] Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
    Kearns, Ben
    Jones, Myfanwy Lloyd
    Stevenson, Matt
    Littlewood, Chris
    [J]. PHARMACOECONOMICS, 2013, 31 (06) : 479 - 488
  • [10] Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone
    Thomas, C.
    Hadaschik, B. A.
    Thueroff, J. W.
    Wiesner, C.
    [J]. UROLOGE, 2009, 48 (09): : 1070 - 1074
1234